Bristol-Myers Squibb stock price forecast: short-term resistance holds as BMY slips 1.5%

Traders Union
All News
Companies
Bristol-Myers slides 1.50% today

Highlights

Bristol-Myers Squibb is experiencing short- to medium-term downside pressure, trading below key short-term averages despite longer-term support.
Momentum and trend indicators are mixed, with weak bullish conviction, overbought short-term conditions, and signs of possible corrective action.
Expected price range for the coming week is $56.75 to $60.60, with a high probability of upward movement if resistance at $59.67 is breached.

Bristol-Myers Squibb ($58.54) is currently trading below the SMA-20 ($59.57) and SMA-50 ($58.75), but well above the SMA-200 ($50.62), indicating short- and medium-term downside pressure while maintaining solid long-term support. The Ichimoku Kijun at $59.67 sits above the current price and acts as immediate resistance.

Momentum signals on D1 are mixed, with sideways ADX (19.90, Neutral) and a negative MACD direction (Sell) hinting at weak bullish conviction and a risk of corrective movement. RSI (46.81, Sell) and Stoch RSI (69.14, Neutral) show the stock is not in oversold territory, while CCI remains neutral. The D1 BBP is overbought (+0.78), reflecting recent buyer dominance that may soon exhaust itself. Awesome Oscillator is neutral, suggesting no reinforcement for the prevailing short-term trend. Bristol-Myers has risen $1.06 (1.84%) over the past week, trading at $58.54 up from last week's close of $57.48, and is positioned in the upper part of the weekly range. Weekly volatility stands at 5.67%. The tone reflects a recovery from the weekly low with buyers reclaiming ground, but Tuesday’s 1.5% decline in today’s session signals some intraday profit-taking or rotation.

Looking ahead, the expected price range for the coming week is $56.75 to $60.60, keeping the forecast anchored within 52-week extremes ($42.52 low, $62.89 high). Based on a strong cluster of weekly bullish signals (RSI-W1, ADX-W1, MACD-W1, and MA-50-W1—all "Buy" or "Strong Buy"), there is a very high probability (more than 80%) that a price increase is more likely than a decline. Baseline scenario: the price consolidates between near-term support at $58.22 and resistance at $59.67. Bullish: a breakout above $59.67 (Kijun and 20-day average) could target the $60.60 area. Bearish: failure to hold above $58.22 could expose the key support zone at $55.77–$54.94 (MA-100 region).

Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Previously it was reported that Bristol-Myers Squibb was experiencing a period of consolidation following earlier signs of medium- and long-term bullish momentum. Building on this, the current assessment highlights a key level near recent resistance that traders should monitor for signs of renewed trend direction in the coming sessions.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.